Tumor of uterus

This early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with stan…

This Phase 3 trial tests a 9-valent HPV vaccine in over 9,000 healthy women aged 18-45. The vaccine targets nine HPV types linked to cervical cancer and genital warts. Researchers compare it to an existing 2-valent vaccine to see if it provides broader protection. The goal is to …

This early-stage trial tests whether three experimental mRNA vaccines can safely teach the immune system to recognize and fight HIV. About 108 healthy, HIV-negative adults aged 18-55 will receive one of the vaccines. The main goal is to check for side effects and see if the vacci…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …

This early-phase trial is testing whether giving heated chemotherapy directly into the abdomen during surgery is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants will receive standard chemotherapy before surgery, and then either heated che…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…

This early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…

This early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…

This study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…

This study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This Phase 3 trial compares a new drug, MK-2870, against standard treatments for people with recurrent or metastatic cervical cancer that has progressed after initial therapy. About 686 participants will receive either MK-2870 or a doctor-chosen standard treatment. The main goal …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…

This study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This phase 2 trial tests whether adding olaparib to selumetinib works better than selumetinib alone for women with recurrent or persistent ovarian or endometrial cancers that have a RAS pathway mutation. Selumetinib blocks enzymes that help cancer grow, while olaparib stops cance…

This phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether combining olaparib and temozolomide works better than standard drugs (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery and has stopped responding to initial chemotherapy. About 74 pa…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…

This Phase II trial is testing whether a combination of two chemotherapy drugs, doxorubicin and trabectedin, can help prevent uterine leiomyosarcoma from coming back after surgery. The study enrolls 48 patients with high-risk, early-stage disease who have had their tumor fully re…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…

This study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This trial investigates whether the immunotherapy drug avelumab, given alone or combined with talazoparib or axitinib, can shrink tumors or slow disease progression in women with recurrent or persistent endometrial cancer. Participants have specific tumor types, including those w…

This early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. Ab…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This phase II trial tests whether simvastatin, a widely used cholesterol medication, can reduce the size of uterine fibroids and ease related symptoms. Researchers will give 60 women either simvastatin or a placebo daily for 12 weeks, measuring fibroid volume by ultrasound and tr…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This early-stage trial is testing a new drug called INCB123667, taken as a tablet, in people with advanced solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with other cancer therapies. The main goals are to…

This early-phase trial tests a new drug that targets a specific gene (EphA2) to slow tumor growth in people with advanced solid tumors that have spread or returned. About 49 participants will receive the drug to find the safest dose and check for side effects. The goal is to cont…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This phase 2 trial tests whether combining internal radiation (brachytherapy) with two immunotherapy drugs, durvalumab and tremelimumab, can help women with gynecologic cancers that are resistant to platinum chemotherapy. The study includes 9 participants with ovarian, endometria…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This study tests whether the immunotherapy drug TSR-042 can help prevent cervical cancer from returning in patients with high-risk locally advanced disease who have completed standard chemo-radiation. About 134 women will receive TSR-042 as a maintenance therapy to see if it exte…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …

This study tests a drug called sacituzumab govitecan in 50 people with endometrial cancer that has returned or not responded to platinum chemotherapy. The drug works by delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or d…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This study tests online adaptive radiotherapy, a type of radiation that adjusts in real-time to target cervical cancer more precisely. By using smaller treatment margins, doctors hope to reduce side effects while still effectively treating the tumor. The trial involves 30 adults …

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This study tests whether adding a new immunotherapy drug (cadonilimab) to chemotherapy before the usual chemoradiation can shrink tumors better in people with locally advanced cervical cancer. About 29 participants will receive the combination, then standard treatment. The goal i…

This phase II trial tests whether adding pterostilbene, an antioxidant found in blueberries, to the hormone drug megestrol acetate can better slow endometrial cancer growth before hysterectomy. About 44 patients will receive either megestrol acetate alone or with pterostilbene fo…

This study tested a combination of two drugs—mirvetuximab soravtansine and pembrolizumab—in 18 people with a specific type of uterine cancer (endometrial cancer) that had returned or persisted and was microsatellite stable (MSS). The goal was to see if the combo could shrink tumo…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for cervical cancer patients also receiving chemotherapy. The goal is to see if the shorter schedule is just as safe and effective, while reducing the number of hospit…

This phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This early-phase study tests a new way to treat advanced solid tumors by combining low-dose radiation with a drug called 5-aminolevulinic acid (ALA). The drug is thought to make cancer cells more sensitive to radiation, allowing lower doses to be used and potentially reducing har…

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-phase study tests whether combining two drugs, DKN-01 and pembrolizumab, can help control advanced or recurrent endometrial cancer that cannot be cured with surgery or radiation. Eight adult women with this type of cancer will receive the combination. The main goals ar…

This study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…

This early-phase study tests whether adding the drug azeliragon to radiation therapy is safe for people whose cancer has spread to the lining of the brain and spinal cord. About 21 adults with solid tumors or aggressive brain cancers will receive the combination. The main goal is…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study compares two surgical approaches for women with middle-to-high risk endometrial cancer that hasn't spread beyond the uterus. One group gets sentinel lymph node sampling (removing only a few key nodes), while the other gets standard pelvic lymphadenectomy (removing many…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…

This Phase 3 trial compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature (dMMR). The goal is to see if pembrolizumab can better delay cancer growth and impro…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This phase II study tests whether the combination of letrozole (Femara) and everolimus (Afinitor) can help control advanced or recurrent endometrial cancer. The trial enrolled 42 participants whose cancer had progressed or returned. Researchers are measuring how many patients res…

This study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…

This early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This phase II trial tests a new biologic drug called ZG005 in 50 adults with advanced solid tumors that have not responded to or are not suitable for standard treatments. Participants receive ZG005 by IV every three weeks. The study measures how many tumors shrink and tracks side…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This Phase 2 trial is testing an experimental drug called PRL3-zumab in 51 people with advanced solid tumors that cannot be removed by surgery or have spread. The drug is given as an IV infusion every two weeks. The main goal is to see how long the cancer stays under control and …

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…

This study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This phase 2 trial tests whether adding a vaccine called PDS0101 to standard chemoradiation is safe and effective for people with advanced cervical cancer. The vaccine trains the immune system to attack HPV-infected tumor cells. About 22 participants will receive the combination,…

This early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…

This study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This study looks at whether giving chemotherapy after surgery can help people with early-stage (stage I-II) endometrial cancer who have a higher risk of the cancer coming back. About 244 patients will either receive six cycles of carboplatin and paclitaxel or simply be observed. …

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests a new drug, MK-2870, against standard chemotherapy in about 710 people with endometrial cancer that has worsened after platinum chemo and immunotherapy. The goal is to see if MK-2870 helps people live longer and delays cancer growth. Participants are randomly ass…

This early-stage trial tests an experimental drug called LY3200882, taken orally, in people with solid tumors. The main goal is to check safety and find the right dose. Some participants also receive other cancer treatments like chemotherapy or radiation. The study involves 223 a…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests whether a program combining phone counseling and personalized text messages can help 360 cervical cancer survivors in Florida quit smoking better than standard quitline services. Participants must have a history of cervical cancer or high-grade cervical dysplasia…

This phase II trial is testing whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 women whose cancer had returned after standard chemotherapy. Researchers a…

This early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…

This study tests whether a low-caffeine green tea extract (EGCG) can shrink uterine fibroids and improve pregnancy and live birth rates in women aged 18-40 who have been trying to conceive for at least six months. Participants take the extract and are monitored for changes in fib…

This study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…

This study tests a new surgical technique to remove large uteri through the vagina using a sealed bag and electric fragmentation. The goal is to avoid abdominal scars and prevent the spread of tissue fragments. Twenty-five women aged 38 to 52 with large uteri are participating. T…

This study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The g…

This early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…

This study tests a web-based tool called the Cancer Tracking System (CATSystem) that sends automated texts and alerts to help women in Kenya get timely cervical cancer screening and follow-up care. About 6,600 women across 10 hospitals will take part, with half the hospitals usin…

This study tests a new drug called PEN-866, which stays in tumor cells longer than normal cells, combined with two standard chemotherapy drugs (vincristine and temozolomide). It is for people aged 12 to 39 with sarcomas (Ewing sarcoma or rhabdomyosarcoma) that have returned or no…

This study tests a fully enclosed protective bag used during laparoscopic myomectomy to remove uterine fibroids. The bag is meant to keep fibroid tissue completely isolated, preventing any leakage or spread during the procedure. Twenty women aged 28-46 with fibroids 6-10 cm will …

This study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…

This early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…

This study tests a combination of two drugs, abemaciclib and letrozole, in people with advanced or recurrent endometrioid endometrial cancer that cannot be cured by surgery or radiation. The main goal is to see how many participants have no cancer growth after 6 months of treatme…

This study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease prog…

This early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…

This study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This study tests an experimental oral drug called Q702 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced esophageal, stomach, liver, or cervical cancer that has worsened after prior treatment. The goal is to see if the combination is safe and can sh…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study tests a combination of three drugs—niraparib, temozolomide, and atezolizumab—in people with advanced solid tumors or extensive-stage small cell lung cancer. The goal is to find the best dose and see if the combination works better than atezolizumab alone as maintenance…

This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…

This Phase 2 trial is testing whether combining two drugs, niraparib and dostarlimab, can help shrink or control cervical cancer that has come back or spread. About 66 women with recurrent or progressive cervical cancer will receive the treatment. The goal is to see how many resp…

This study tests a new drug combination (E7389 liposomal formulation plus nivolumab) in 125 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The study is for people …

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This study tests a combination of two drugs—TG4001 (a biologic that targets HPV) and avelumab (an immunotherapy)—in people with advanced HPV-16 cancers that cannot be removed by surgery or cured by radiation. The trial has two phases: first, to find a safe dose, and second, to se…

This early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This study tests an experimental drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose, and then expanding to see how well the drug shrinks tumors. About 725 parti…

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…

This early-phase trial aimed to test whether curcumin (the active compound in turmeric) could safely help treat cervical precancer (CIN3). It planned to give 500 mg of curcumin twice daily for 12 weeks to women with CIN3. However, the study was withdrawn before enrolling any part…

This early-stage study tests a new drug called SHR-4712 in 15 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and how the body processes it. Participants receive the drug until their disease gets worse or …

This early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…

This early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This study tests a new drug called BT7480, given alone or with another drug (nivolumab), in 200 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shrinks tumors. It is an early-stage t…

This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This early-stage study tests a new drug, TORL-2-307-ADC, in 163 people with advanced solid tumors like stomach, pancreas, or esophageal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have measurable disease and be well enough for …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of ut…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This early-stage study tests two experimental immunotherapy drugs, ABBV-927 and ABBV-181, in people with advanced solid tumors that have not responded to other treatments. The main goal is to find the safest dose and understand how the drugs move through the body. About 163 parti…

This early-phase study tests a new drug called ADG206 in 14 people with advanced solid tumors that have not responded to standard treatments. ADG206 is an antibody designed to activate the immune system by targeting CD137, a protein on immune cells. The main goals are to check sa…

This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This study tests whether a structured diet, exercise, and lifestyle program can help prevent uterine fibroids from returning after surgery. Researchers will follow 100 women aged 18-50 who recently had fibroids removed and are currently fibroid-free. The goal is to see if the pro…

This early-phase trial tests whether adding an immune-boosting drug (TSR-042) to standard radiation therapy is safe and effective for people with inoperable endometrial cancer. Ten participants with early-stage disease will receive both treatments. The goal is to see if the combi…

This phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalima…

This study compares two surgical methods for early-stage cervical cancer: minimally invasive (keyhole or robot-assisted) surgery and traditional open abdominal surgery. Researchers will follow 2000 patients for up to 5 years to see which approach leads to better survival and fewe…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This early-stage trial tests a new drug called DM919, alone or with pembrolizumab, in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe and effective dose and see if it can shrink tumors. Participants receive the drug by …

This study tests a two-drug combination (tucatinib and trastuzumab) in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control tumors. About 217 participants with various cancers (like lung, uterine, or bile duct) wi…

This early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …

This early-stage trial tests an experimental oral drug called PRJ1-3024 in 39 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may s…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This study was designed to compare chemo-immunotherapy (chemotherapy plus a PD-1 inhibitor) against standard chemoradiotherapy for cervical cancer patients whose cancer had spread to lymph nodes after surgery. The goal was to see which approach better prevented cancer from return…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow cancer growth. About 112 participants …

This study tests the safety and effectiveness of neratinib, a targeted cancer drug, in children whose solid tumors, brain tumors, lymphoma, or leukemia have come back or not responded to standard treatments. The drug is taken by mouth daily in 28-day cycles. The main goal is to f…

This study tests a drug called larotrectinib in children and young adults (up to age 30) with certain cancers that have a specific genetic change called a TRK fusion. The goal is to see if the drug can shrink solid tumors or control leukemia that has returned. The drug works by b…

This early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the c…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, designed to target specific cancer markers (EphA2 and KRAS mutations). The vaccine is given along with chemotherapy and two immunotherapy drugs. The study includes 9 adults with advanced s…

This early-phase study tests a new drug called BR115 in 120 people with advanced solid tumors that have not responded to other treatments. The main goal is to check safety and find the right dose. Participants receive the drug weekly after an initial two doses, and the study moni…

This study tests a new drug called MHB039A, a bispecific antibody, in 196 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. Participants receive the drug and are monitored for side effects and t…

This early-stage trial is testing a new drug called HFB200301, either alone or with another drug (tislelizumab), in 72 adults with advanced solid tumors like lung, stomach, or skin cancer. The main goal is to check safety and find the best dose. Researchers will also watch for an…

This Phase 3 trial is testing whether adding the immunotherapy AK104 to standard chemotherapy (with or without bevacizumab) helps people with advanced cervical cancer that cannot be cured by surgery or radiation. About 445 participants will receive either the drug combo or a plac…

This early-stage trial tests a modified herpes virus (BS006) that is injected directly into tumors to kill cancer cells and activate the immune system. It involves 29 adults with advanced solid tumors like melanoma or breast cancer. The study is currently suspended, and its main …

This early-stage study tests a new tablet called BB3008 in about 42 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body processes the drug. Participants take the tablet by m…

This study tests a new drug called MHB036C, an antibody-drug conjugate, in 200 adults with advanced solid tumors. The trial has two phases: first to find the safest dose, then to see how well it works. Researchers will monitor side effects and measure drug levels in the blood.

This study tests an experimental drug called BT5528, given alone or with another drug (nivolumab), in people with advanced solid tumors that have high levels of a protein called EphA2. The cancers include ovarian, bladder, lung, breast, head and neck, and stomach cancers. The mai…

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…

This study tests an experimental drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors, including lung, head and neck, kidney, and skin cancers. The first part of the trial finds the safest dose, …

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This early-stage study tests a new experimental drug called GSK6097608, given alone or with other cancer medicines, in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Abo…

This study tests a new drug called TSR-022 in people with advanced solid tumors that have not responded to other treatments. The drug is an antibody that targets a protein on immune cells to help fight cancer. The trial has two parts: first, finding the safest dose, and then test…

This early-stage trial is testing whether a combination of three widely used drugs—metformin (for diabetes), digoxin (for heart conditions), and simvastatin (for cholesterol)—can be safely given to people with advanced pancreatic cancer or other solid tumors that have stopped res…

This phase 2 study is testing a combination of two drugs, SKB264 and pembrolizumab (Keytruda), in 240 people with certain advanced solid tumors, including cervical, urothelial, ovarian, prostate, and endometrial cancers. The goal is to see if the combination is safe and effective…

This early-phase trial tests a new drug called TTX-MC138 in 16 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink or stabilize tumors. It is an open-label study, meaning everyone know…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…

This phase 2a trial tests a new form of the chemotherapy drug gemcitabine (FF-10832) given alone or with the immunotherapy pembrolizumab (Keytruda) in 120 adults with advanced bladder or non-small cell lung cancer. The study first checks safety and finds the best dose, then looks…

This early-phase trial tests whether moving a piece of a woman's own ovary to the fatty tissue of her inner thigh before pelvic radiation can keep her ovaries working. The study includes 22 women aged 35 or younger with locally advanced cervical cancer. The goal is to see if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current s…

This early-phase study tests how well a special PET-CT scan called FAZA can measure oxygen levels in solid tumors like breast, colorectal, and pancreatic cancers. About 25 participants will receive the FAZA tracer and undergo imaging to see if the results are consistent over time…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…

This study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor's sample. It involves 750 women referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable alternative to traditional pelvic exa…

This study tests whether a combined PET/MRI scan can more accurately show how deep cervical cancer has grown and whether it has spread to lymph nodes. About 25 people with early-stage cervical cancer that can be removed by surgery will get the scan before their operation. The goa…

This study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…

This study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if…

This study evaluates different cervical cancer screening methods using HPV testing in Botswana, involving 3000 women aged 25 and older. Researchers compare HPV genotype restriction with visual inspection to find the most accurate way to detect high-grade cervical dysplasia. The g…

This study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. …

This study was designed to compare the standard Pap smear with a new blood test that looks for three proteins linked to cervical cell changes. It planned to include adults aged 18-85 in good health. However, the study was withdrawn before enrolling any participants, so no results…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study explores whether a non-invasive electroacupuncture technique can detect signs of persistent viruses, like HPV and SARS-CoV-2, in 30 women with advanced cervical cancer. Researchers will measure electrical responses at specific body points to see if they match viral pre…

This study tests whether injecting a radioactive sugar tracer (18F-FDG) into the cervix before a PET/CT scan can better show which pelvic lymph nodes contain cancer in women with early-stage cervical or high-grade endometrial cancer. The goal is to improve surgical planning by mo…

This study looks at whether offering HPV self-sampling kits by mail, pharmacy, or clinic can make cervical cancer screening easier. One thousand women aged 25-65 in Quebec will try different ways to get and return the kit. The goal is to see which method works best and if women f…

This study is testing whether women in Indonesia can successfully collect their own samples for HPV testing, which could make cervical cancer screening more accessible. Researchers will enroll 8,000 women aged 30-69 who haven't been screened recently. The goal is to see if self-c…

This trial tests two strategies for preventing cervical cancer in women living with HIV in Tanzania. Both strategies involve HPV self-sampling and visual checks of the cervix, but they differ in the timing of HPV vaccination. The study aims to see which approach better reduces pr…

This study in Malawi tests different methods—like in-person or virtual training, coaching, and visual reminders—to help health workers talk about and offer cervical cancer prevention to women and girls in HIV care. About 7,000 people will take part. The goal is to find the most e…

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …

This trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…

This study looks at whether women in rural Uganda can screen themselves for cervical cancer using a simple HPV test at home. Over 2,500 women aged 25-49 will collect their own samples during community health campaigns. The goal is to see if this approach increases screening rates…

This study compares two ways to screen for cervical cancer: a Pap smear every 2.5 years versus an HPV test every 5 years. Over 76,000 women aged 25-69 in Australia are taking part, including those who received the HPV vaccine and those who did not. The goal is to see if the less …

This study looks at whether giving women a free self-sampling device (SSD) through their general practitioner (GP) can increase cervical cancer screening rates among those who haven't had a smear test in 6 years. About 3,375 women aged 31-64 in Flanders will be randomly assigned …

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This trial is testing whether watching educational videos before minimally invasive gynecologic surgery can lower patient anxiety. Participants are randomly assigned to either watch the videos or receive standard counseling alone. The study measures anxiety and preparedness throu…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…

This study tests a program called ENABLE Cornerstone, where specially trained lay coaches provide support to family caregivers of people with advanced cancer. The coaches help caregivers manage stress, improve coping skills, and plan for the future through phone or in-person sess…

This study compares two types of radiation therapy—proton therapy and standard intensity-modulated radiation therapy (IMRT)—given after surgery for cervical or endometrial cancer. The goal is to see if proton therapy causes fewer bowel side effects. About 120 women will fill out …

This study tests whether yoga therapy can improve physical and emotional well-being in people with cervical cancer undergoing chemotherapy and radiation. About 40 participants with stage IB2 to IIIB cervical cancer will attend yoga classes or receive a DVD. The main goal is to se…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a newer type of radiation therapy called online adaptive radiotherapy (oART) for people who have had surgery for endometrial or cervical cancer. The goal is to see if using smaller treatment margins can reduce side effects while still effectively targeting any re…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether applying an ice pack to the lower abdomen after vNOTES hysterectomy can lower pain and reduce the need for painkillers. 122 women having surgery for benign conditions will be randomly assigned to receive either standard care or standard care plus ice pack…

This study tests whether adding a special yoga and physiotherapy program to standard care can lower stress in women receiving brachytherapy for cervical cancer. About 98 women will take part. The program includes gentle movement and breathing exercises designed to be safe during …

This study tests whether a 12-week health education program can improve lifestyle, quality of life, and mental health in 28 women with cervical cancer. Participants receive a booklet and attend meetings and social media sessions covering exercise, diet, self-esteem, and more. The…

This study tests whether group or one-on-one peer support helps Black patients with endometrial cancer complete their treatment and feel less isolated. About 252 participants will be randomly assigned to group support, one-on-one peer calls, or usual care. The main goal is to see…

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study looks at whether listening to a self-hypnosis audio before surgery can help women with gynecologic cancer feel less pain and recover faster. About 152 patients having surgery for cancers of the female reproductive system will be randomly assigned to either usual care o…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests an online program called Day by Day for women with stage III or IV gynecologic cancer who have high fear of their cancer getting worse or coming back. The program teaches skills to manage anxiety and reframe worries. About 23 women will try the program for 12 wee…

This study tests whether giving vitamin C through an IV before and during a hysterectomy can reduce blood loss. Forty women with fibroids or adenomyosis will receive either vitamin C or a placebo. Researchers will measure blood loss during surgery and check if vitamin C helps mai…

This study is testing a program called Journey Ahead, designed to help women with gynecologic cancers improve their coping and communication skills. The researchers are enrolling 30 women who have been diagnosed with ovarian, endometrial, cervical, or uterine cancer. Participants…

This study looks at whether adding a steroid to a nerve block can better control pain after a procedure that treats uterine fibroids or adenomyosis. About 28 women aged 30 to 60 will receive either a standard numbing nerve block or one with added steroids. Researchers will measur…

This study looks at whether a 10-week exercise program done at home can improve physical fitness in women who have finished treatment for endometrial cancer. Ten participants will do exercises like chair stands and arm curls, guided by video coaching. The goal is to see if this a…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This study looks at risk factors for endometrial cancer in Black women, a group that may face different risks. Researchers will compare women recently diagnosed with the cancer to healthy volunteers, using questionnaires and interviews. The goal is to understand what factors matt…

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if the…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…

This study aims to learn more about how oxygen, metabolism, and blood supply work in high-grade brain tumors and cervical cancers. About 20 adults with these cancers will receive special PET and MRI scans. No treatment is given; the goal is to better understand tumor biology.

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…

This study tested whether custom 3D printed applicators could improve radiation delivery in brachytherapy for gynecological cancers. Thirteen patients with cervical, uterine, vaginal, or vulvar cancer received MRI-guided treatment using these personalized tools. The goal was to s…

This study looks at how people with both cancer and heart failure feel day-to-day. Researchers will ask 100 participants about their symptoms and quality of life using simple questionnaires. No new treatments are tested—the goal is to better understand the challenges these patien…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, col…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This observational study follows 168 women living with HIV in Zimbabwe who have been treated for cervical pre-cancer. Researchers want to learn how often the disease comes back and whether HPV or DNA tests can predict recurrence. Participants will be monitored every six months fo…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This early-phase trial is testing the drug triapine in 12 women with a rare and aggressive type of uterine cancer called uterine serous adenocarcinoma. Participants receive a single dose of triapine before their scheduled hysterectomy, and researchers analyze tissue samples to se…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study follows about 700 women for up to 12 years after they had a uterine-sparing fibroid treatment, such as myomectomy or uterine artery embolization. Researchers want to see how long these treatments last before another procedure is needed, and how women's symptoms and qua…

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This large study in Mozambique is testing whether offering HPV self-testing alongside voluntary family planning services increases the number of women who get screened for cervical cancer. Over 9,000 women aged 30–49 or living with HIV are taking part. The goal is to see if integ…

This study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better p…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study looks at pelvic floor problems and quality of life in people who survived uterine cancer. Researchers will use questionnaires to gather information from about 310 survivors treated with surgery at MD Anderson between 2006 and 2017. The goal is to better understand how …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 people who are currently cancer-free will answer questionnaires about their quality of life, anxiety, sexual health, and more. The goal is to learn what matt…

This study aims to find biological markers (biomarkers) that show which cervical cancers have low oxygen levels, making them harder to treat with standard radiation. About 30 patients with advanced cervical cancer will have special MRI scans and tumor biopsies before and during t…

This study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …

This registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…

This study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…

This early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…

This nationwide registry follows 578 women with uterine fibroids who choose either radiofrequency ablation (Acessa) or myomectomy. Researchers track symptom changes, quality of life, and need for repeat treatment over three years. The goal is to understand which procedure provide…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study is testing whether a special PET scan dye called 18F-FAZA can measure low oxygen levels (hypoxia) in cervix cancer tumors. About 30 adults with cervix cancer will receive the dye before starting standard treatment with radiation and chemotherapy. The goal is to see if …

This study measures oxygen levels inside cervical cancer tumors during a type of radiation called brachytherapy. Ten adult patients with cervical cancer will have tiny oxygen sensors placed in their tumors during the procedure. The goal is to see if oxygen levels relate to how we…

This study aims to find the genetic changes that cause some women to have repeated molar pregnancies (abnormal growths in the womb). Researchers will analyze DNA from blood and tissue samples of up to 100 women and their relatives. The goal is to discover new genes linked to this…

This study looks at how a person's genes and medical history might help predict nerve damage caused by chemotherapy. Researchers will follow 300 people with certain cancers who are scheduled for specific chemo drugs. The goal is to find patterns that could help prevent or reduce …

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…

This study looks at how diet, lifestyle, and genetics influence the risk of endometrial cancer. Researchers will compare women who have or had the cancer with those who do not, using surveys and genetic analysis. The goal is to identify factors that may increase or decrease risk,…

This phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while s…

This study watches a single gynecology resident as they learn to perform a hysterectomy through the vagina using a special camera, leaving no belly scars. The goal is to see how quickly the resident improves, measuring surgery time and any complications. Nineteen women with benig…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study takes a small piece of a patient's cancer and grows it in special mice. Doctors then test many different drugs on the mouse tumor to see which ones work best. The results are shared with the patient's oncologist, who decides if and how to use the information. The goal …

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …

This study tracks how the tumor and nearby organs move during radiotherapy for cervix cancer. By taking many MRI scans during treatment, researchers hope to better target the tumor and spare healthy tissue. The goal is to reduce side effects and improve outcomes. The study involv…

This study looks at whether oxygen levels and internal pressure in cervical tumors can help predict how well radiation therapy works. Researchers measured these factors in 346 patients with cervical cancer before and during treatment. The goal is to understand why some tumors res…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study looks at how low oxygen levels and fluid pressure inside cervical cancer tumors relate to how well radiation therapy works. Researchers will measure these factors in 500 patients before and during treatment. The goal is to find the best way to identify which patients m…

This study follows women who have had pelvic exenteration—a surgery removing the lower colon, rectum, and bladder—for gynecologic cancers like cervical or endometrial cancer. Researchers want to see if factors like tumor size or surgery type affect complications, quality of life,…

This study is testing whether doing a special PET scan during radiation treatment can help doctors adjust the plan to better target tumors and spare healthy tissue. It involves 90 adults with cervical, vulvar, esophageal, or anal cancer. The goal is to see if this approach improv…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer returning or getting worse. The study planned to compare the online program to standard educational materials. Howev…

This study collects information from about 300 endometrial cancer patients across Asia to see how doctors use cancer cell features to choose treatments. The goal is to learn which patients need stronger therapy and which can avoid extra side effects. No new treatments are tested—…

This pilot study aimed to see if a mobile health app could help track symptoms and quality of life in people with recurrent head and neck or gynecologic cancers. Participants would have used the app to report their feelings, side effects, and barriers to care. However, the study …

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study tests a program called the Sexual Health Empowerment (SHE) Project for women who are about to leave jail. The goal is to improve their understanding of cervical cancer, breast cancer, contraception, and sexually transmitted diseases. About 279 women will take part, and…

This study looks at whether doctors can safely remove fewer lymph nodes during surgery for endometrial cancer by using a quick lab test during the operation. The goal is to reduce side effects like pain and swelling while still catching cancer that has spread. About 400 women wit…

This study looks at whether surgically removing uterine fibroids (myomectomy) changes blood flow in the main uterine artery. Researchers will use Doppler ultrasound to measure blood flow before and about 40 days after surgery in 70 premenopausal women. The goal is to provide new …

This study tests a personalized post-cancer care plan for women who have finished treatment for ovarian or endometrial cancer. About 99 participants will receive a day of support care and a tailored plan to address their needs. The goal is to see if this approach improves their l…

This study enrolls 2,300 Kenyan women and girls to improve cervical cancer prevention. Women provide self-collected swabs for HPV testing and undergo standard visual screening. The goal is to see if self-testing is as good as or better than current methods, and to understand what…

This study looks at whether offering cervical cancer screening in the emergency department helps more people get tested. About 200 women and transgender/non-binary individuals with a cervix, aged 25-65, will be offered a self-sampling kit or clinic referral. Researchers will call…

This study aims to find the best MRI settings for the MR-linac, a machine that combines MRI and radiation therapy. Researchers will test different scan parameters in cancer patients and healthy volunteers to get clearer, more accurate images. The goal is to improve radiation ther…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…

This study looks at whether long-term inflammation raises the risk of endometrial cancer. Researchers are collecting blood and urine samples from 191 women having hysterectomy for either cancer or non-cancer reasons. They will compare markers of inflammation to better understand …

This study tests whether community education and support can increase the number of women in Kenya who get screened for breast and cervical cancer. Researchers will enroll 5,400 women aged 30-55 and track how many complete recommended screenings and follow-up care. The goal is to…

This study uses a survey to understand why transgender men (people assigned female at birth who identify as male) in France may not get screened for cervical cancer. Researchers will ask 300 participants aged 25–65 about their screening history and what helps or hinders them. The…

This study screens up to 1,150 people with advanced solid tumors like head and neck, cervical, or lung cancer. Researchers test blood and tumor samples to see if participants have the right genetic markers for future T-cell therapy trials. The goal is to find who might benefit fr…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study aimed to see if a type of PET/MRI scan could predict which women with early endometrial cancer or a precancerous condition would respond to hormone therapy. It planned to enroll 8 women and follow them for 6 months. However, the study was withdrawn before any participa…

This study was designed to track hair loss in women with uterine fibroids who are taking the medication Oriahnn. Researchers planned to follow about 1,600 women for up to 24 months, using questionnaires and scalp photos to see how common hair loss is, when it starts, and if it go…

This study looks at 180 women in India with cervical cancer who are receiving standard chemoradiation. Half are HIV-positive and half are HIV-negative. Researchers want to see if HIV affects how often patients complete treatment and how severe side effects are. The goal is to lea…